Hyperlipoproteinemia: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) |
Tarek Nafee (talk | contribs) |
||
Line 150: | Line 150: | ||
| | | | ||
|- | |- | ||
| rowspan=" | | rowspan="10" |'''Secondary Hyperlipoprotenemia''' | ||
|Diabetes Mellitus | |Diabetes Mellitus | ||
| | | | ||
Line 164: | Line 164: | ||
| | | | ||
|- | |- | ||
|Alcohol Abuse | |||
| | | | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Estrogen Therapy | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Glucocorticoid therapy | |||
| | | | ||
| | | | ||
Line 177: | Line 203: | ||
| | | | ||
|- | |- | ||
|Renal Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | |||
| | |||
|- | |||
|Obesity | |||
| | | | ||
| | | | ||
Line 190: | Line 229: | ||
| | | | ||
|- | |- | ||
|High-fat diet | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |||
|Poor physical activity | |||
| | | | ||
| | | | ||
Line 203: | Line 255: | ||
| | | | ||
|- | |- | ||
|Paraproteinemic disorders | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | |||
| | |||
| | |||
|- | |||
|Hypothyroidism | |||
| | | | ||
| | | |
Revision as of 20:29, 8 November 2016
Hyperlipoproteinemia Microchapters |
ACC/AHA Guideline Recommendations |
Intensity of statin therapy in primary and secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Synopsis
Hyperlipoproteinemia | Synonyms | Problems | Labs description | Treatment |
---|---|---|---|---|
Type I | Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia | Decreased lipoprotein lipase (LPL) or altered ApoC2 | Elevated chylomicrons | Diet control |
Type IIa | Polygenic hypercholesterolaemia or familial hypercholesterolemia | LDL receptor deficiency | Elevated LDL only | Bile acid sequestrants, statins, niacin |
Type IIb | Combined hyperlipidemia | Decreased LDL receptor and increased ApoB | Elevated LDL, VLDL and triglycerides | Statins, niacin, gemfibrozil |
Type III | Familial Dysbetalipoproteinemia | Defect in ApoE synthesis | Increased IDL | Drug of choice: Gemfibrozil |
Type IV | Endogenous Hyperlipemia | Increased VLDL production and decreased elimination | Increased VLDL | Drug of choice: Niacin |
Type V | Familial Hypertriglyceridemia | Increased VLDL production and decreased LPL | Increased VLDL and chylomicrons | Niacin, gemfibrozil |
Differential Diagnosis
Diseases | Mode of Inheritance | Laboratory Findings | Other Findings | Management | Complications | Prognosis | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Lipid Profile | Genetic mutations | |||||||||||
Total Cholesterol | LDL | HDL | Triglycerides | Plasma Appearance | ||||||||
Primary Hyperlipoprotenemia | Type I | ↓ | ↑ | Creamy | ||||||||
Type IIA | ||||||||||||
Type IIB | ||||||||||||
Type III | ||||||||||||
Type IV | ||||||||||||
Type V | ||||||||||||
Secondary Hyperlipoprotenemia | Diabetes Mellitus | |||||||||||
Alcohol Abuse | ||||||||||||
Estrogen Therapy | ||||||||||||
Glucocorticoid therapy | ||||||||||||
Renal Disease | ||||||||||||
Obesity | ||||||||||||
High-fat diet | ||||||||||||
Poor physical activity | ||||||||||||
Paraproteinemic disorders | ||||||||||||
Hypothyroidism |
Classification
Hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Type I: Familial hyperchylomicronemia | Type II | Type III: Dysbetalipoproteinemia | Type IV: Primary hypertriglyceridemia | Type V: Mixed hyperlipoproteinemia | |||||||||||||||||||||||||||||||||||||||||||||||||||
Type A: Familial hypercholesterolemia | Type B: Familial combined hyperlipidemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||